Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 2Tumor-Agnostic 1Thoracic 1Dermatologic 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Electroporation × Tumor-Agnostic × Clear all
NCT02822066 2016-07-04

Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas

First Affiliated Hospital of Zhejiang University

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡